Results 181 to 190 of about 44,418 (298)

Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2661-2671, April 2026.
Abstract Aims This study aims to compare the risk of major adverse cardiovascular events (MACE) among United States individuals with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) treated with once‐weekly semaglutide vs. dulaglutide.
Xi Tan, Yuanjie Liang, Lin Xie, Joanna Harton, Cynthia Gutierrez, Chalak Muhammad, Caroline Swift, Adam de Havenon   +7 more
wiley   +1 more source

Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: target trial emulation. [PDF]

BMJ Med
Xie Y, Choi T, Al-Aly Z.
europepmc   +1 more source

Pharmacogenetics of sulfonylurea: Presence of CYP2C9*2, CYP2C9*3 and a novel allele, CYP2C9*61, in Type 2 diabetes patients under sulfonylurea therapy.

, 2020
Sumaira Deen Muhammad, Hazar Khan, Mushtaq Hussain, Tehseen Fatima, Darshan Kumar, Rahimullah Rahi, Mahayrookh Asif, Akhter Ali Balooch   +7 more
openalex   +1 more source

Risk of acute pancreatitis with DPP‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3033-3043, April 2026.
Abstract Aims We investigated whether dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use was associated with a higher risk of acute pancreatitis compared with sodium–glucose cotransporter 2 inhibitor (SGLT2i) use in antidiabetic medication‐naïve individuals.
Takashi Tatewaki, Akira Okada, Yuya Kimura, Hideo Yasunaga   +3 more
wiley   +1 more source

Understanding Diabetes Distress: A Study of Contributing Factors Among Adults With Type 2 Diabetes in Rural East Godavari, Andhra Pradesh. [PDF]

Cureus
Meka RJ, Sundaram M S, Rani K S G, Mani V, Natrajan M.   +4 more
europepmc   +1 more source

Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United States

, 2022
Julie Z. Zhao, Eric D. Weinhandl, Angeline M. Carlson, Wendy L. St. Peter   +3 more
openalex   +1 more source

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3126-3136, April 2026.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Toshiyuki Ko, Kazuki Aoyama, Takashin Nakayama, Yuya Kimura, Katsuhiko Fujiu, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Koichi Node, Masaomi Nangaku, Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi   +16 more
wiley   +1 more source

Identifying high-risk combinations of metformin during COVID-19. [PDF]

PLoS One
Dimnjaković J, Buble T, Poljičanin T, Brborović H, Brađašević E, Brborović O.   +5 more
europepmc   +1 more source

Rationale and design of a parallel randomised trial of a plant‐based intensive lifestyle intervention for diabetes remission: The REmission of diabetes using a PlAnt‐based weight loss InteRvention (REPAIR) trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2627-2641, April 2026.
Abstract Aims As type 2 diabetes (T2D) continues to rise globally and remains a major driver of cardiovascular disease, its remission has emerged as a therapeutic target. Current evidence supports bariatric surgery and low‐calorie diets with meal replacements.
Brighid McKay, Dayana El Chaar, Melanie Paquette, Michael Vallis, Diana Sherifali, Paul Oh, Susan Marzolini, Kaberi Dasgupta, Gillian Booth, Mike Lean, Hertzel C. Gerstein, Jordi Salas‐Salvadó, Jacqueline L. Beaudry, Christopher P. F. Marinangeli, Russell J. de Souza, Lawrence A. Leiter, Cyril W. C. Kendall, David J. A. Jenkins, John L. Sievenpiper, Laura Chiavaroli   +19 more
wiley   +1 more source

Predictors of Glycemic Response to Sulfonylurea Therapy in Type 2 Diabetes Over 12 Months: Comparative Analysis of Linear Regression and Machine Learning Models. [PDF]

JMIR Diabetes
Garg S, Kitchen R, Gupta R, Trucco E, Pearson E.   +4 more
europepmc   +1 more source